United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8) - efavirenz 50 mg - efavirenz capsules in combination with other antiretroviral agents are indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg. - efavirenz capsules are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of this product. - coadministration of efavirenz with elbasvir and grazoprevir is contraindicated [see  warnings and precautions (5.1)  and drug interactions (7.1) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to efavirenz during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry at 1-800-258-4263. risk summary there are retrospective case reports of neural tube defects in infants whose mothers were exposed to efavirenz-containing regimens in the first trimester of pregnancy. prospective pregnancy data from the antiretroviral pregnancy registry are not sufficient to adequately assess this risk. available data from the antiretroviral pregnancy registry show no difference in the risk of overall major birth defects compared to the background rate for major birth defects of 2.7% in the u.s. reference population of the metropolitan atlanta congenital defects program (macdp). although a causal relationship has not been established between exposure to efavirenz in the first trimester and neural tube defects, similar malformations have been observed in studies conducted in monkeys at doses similar to the human dose. in addition, fetal and embryonic toxicities occurred in rats, at a dose ten times less than the human exposure at recommended clinical dose. because of the potential risk of neural tube defects, efavirenz should not be used in the first trimester of pregnancy. advise pregnant women of the potential risk to a fetus. data human data there are retrospective postmarketing reports of findings consistent with neural tube defects, including meningomyelocele, all in infants of mothers exposed to efavirenz-containing regimens in the first trimester. based on prospective reports from the antiretroviral pregnancy registry (apr) of approximately 1000 live births following exposure to efavirenz-containing regimens (including over 800 live births exposed in the first trimester), there was no difference between efavirenz and overall birth defects compared with the background birth defect rate of 2.7% in the u.s. reference population of the metropolitan atlanta congenital defects program. as of the interim apr report issued december 2014, the prevalence of birth defects following first-trimester exposure was 2.3% (95% ci: 1.4% to 3.6%). one of these prospectively reported defects with first-trimester exposure was a neural tube defect. a single case of anophthalmia with first-trimester exposure to efavirenz has also been prospectively reported. this case also included severe oblique facial clefts and amniotic banding, which have a known association with anophthalmia. animal data effects of efavirenz on embryo-fetal development have been studied in three nonclinical species (cynomolgus monkeys, rats, and rabbits). in monkeys, efavirenz 60 mg/kg/day was administered to pregnant females throughout pregnancy (gestation days 20 through 150). the maternal systemic drug exposures (auc) were 1.3 times the exposure in humans at the recommended clinical dose (600 mg/day), with fetal umbilical venous drug concentrations approximately 0.7 times the maternal values. three of 20 fetuses/infants had one or more malformations; there were no malformed fetuses or infants from placebo-treated mothers. the malformations that occurred in these three monkey fetuses included anencephaly and unilateral anophthalmia in one fetus, microphthalmia in a second, and cleft palate in the third. there was no noael (no observable adverse effect level) established for this study because only one dosage was evaluated. in rats, efavirenz was administered either during organogenesis (gestation days 7 to 18) or from gestation day 7 through lactation day 21 at 50, 100, or 200 mg/kg/day. administration of 200 mg/kg/day in rats was associated with increase in the incidence of early resorptions; and doses 100 mg/kg/day and greater were associated with early neonatal mortality. the auc at the noael (50 mg/kg/day) in this rat study was 0.1 times that in humans at the recommended clinical dose. drug concentrations in the milk on lactation day 10 were approximately 8 times higher than those in maternal plasma. in pregnant rabbits, efavirenz was neither embryo lethal nor teratogenic when administered at doses of 25, 50, and 75 mg/kg/day over the period of organogenesis (gestation days 6 through 18). the auc at the noael (75 mg/kg/day) in rabbits was 0.4 times that in humans at the recommended clinical dose. risk summary the centers for disease control and prevention recommend that hiv-infected mothers not breastfeed their infants to avoid risking postnatal transmission of hiv. because of the potential for hiv transmission in breastfed infants, advise women not to breastfeed. because of potential teratogenic effects, pregnancy should be avoided in women receiving efavirenz [see use in specific populations (8.1)]. pregnancy testing females of reproductive potential should undergo pregnancy testing before initiation of efavirenz. contraception females of reproductive potential should use effective contraception during treatment with efavirenz and for 12 weeks after discontinuing efavirenz due to the long half-life of efavirenz. barrier contraception should always be used in combination with other methods of contraception. hormonal methods that contain progesterone may have decreased effectiveness [see drug interactions (7.1)] . the safety, pharmacokinetic profile, and virologic and immunologic responses of efavirenz were evaluated in antiretroviral-naive and -experienced hiv-1 infected pediatric patients 3 months to 21 years of age in three open-label clinical trials [see adverse reactions (6.2) , clinical pharmacology (12.3) , and clinical studies (14.2) ]. the type and frequency of adverse reactions in these trials were generally similar to those of adult patients with the exception of a higher frequency of rash, including a higher frequency of grade 3 or 4 rash, in pediatric patients compared to adults [see  warnings and precautions (5.8)  and adverse reactions (6.2) ]. use of efavirenz in patients younger than 3 months of age or less than 3.5 kg body weight is not recommended because the safety, pharmacokinetics, and antiviral activity of efavirenz have not been evaluated in this age group and there is a risk of developing hiv resistance if efavirenz is underdosed. see  dosage and administration (2.2) for dosing recommendations for pediatric patients. clinical studies of efavirenz did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. in general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other therapy. efavirenz is not recommended for patients with moderate or severe hepatic impairment because there are insufficient data to determine whether dose adjustment is necessary. patients with mild hepatic impairment may be treated with efavirenz without any adjustment in dose. because of the extensive cytochrome p450-mediated metabolism of efavirenz and limited clinical experience in patients with hepatic impairment, caution should be exercised in administering efavirenz to these patients [see  warnings and precautions (5.9)  and clinical pharmacology (12.3) ] .

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - glucagon hydrochloride (unii: 1h87nvf4db) (glucagon - unii:76la80ig2g) - glucagon 1 mg in 1 ml - glucagen is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes. glucagen is indicated as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. glucagen is contraindicated in patients with: risk summary available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation. in rat and rabbit reproduction studies, no embryofetal toxicity was observed with glucagon administered by injection during the period of organogenesis at doses representing up to 100 and 200 times the human dose, respectively, based on body surface area (mg/m2 ) (see data). the estimated background

United States - English - NLM (National Library of Medicine)

sterling knight pharmaceuticals,llc - cyclobenzaprine hydrochloride (unii: 0ve05jys2p) (cyclobenzaprine - unii:69o5wqq5ti) - cyclobenzaprine hydrochloride 5 mg - cyclobenzaprine hydrochloride tablets, usp are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion and restriction in activities of daily living. cyclobenzaprine hydrochloride tablets, usp should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. cyclobenzaprine hydrochloride tablets, usp have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. hypersensitivity to any component of this product. concomitant use of monoamine oxidase (mao) inhi

United States - English - NLM (National Library of Medicine)

pharma health llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.

United States - English - NLM (National Library of Medicine)

1201258 ontario inc. o/a nanz pharma - 10% povidone iodine solution usp, (1% available iodine) - topical antifungal for the treatment of athlete's foot, jock itch, and ringworm for the effective relief of burning, cracking, discomfort, redness, scaling, soreness, and chafing that is associated with jock itch.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose,sodium chloride - solution - 10,0.45 %,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose - intravenous infusion - 10 %

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose - solution for injection - 10 %

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - benzoyl peroxide 10%{relative};   - topical gel - 10% w/w - active: benzoyl peroxide 10%{relative}   excipient: acrylates copolymer carbomer 940 colloidal silicon dioxide disodium edetate dihydrate docusate sodium glycerol poloxamer propylene glycol sodium hydroxide water - latest regulatory activity

New Zealand - English - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - benzoyl peroxide 10%{relative} (as hydrous) - topical gel - 10 % - active: benzoyl peroxide 10%{relative} (as hydrous) excipient: carbomer 940 colloidal silicon dioxide disodium edetate dihydrate docusate sodium poloxamer propylene glycol purified water